...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biological trace element research >An Advanced Formulation of a Magnesium Dietary Supplement Adapted for a Long-Term Use Supplementation Improves Magnesium Bioavailability: In Vitro and Clinical Comparative Studies
【24h】

An Advanced Formulation of a Magnesium Dietary Supplement Adapted for a Long-Term Use Supplementation Improves Magnesium Bioavailability: In Vitro and Clinical Comparative Studies

机译：适用于长期使用补充的镁膳食补充剂的先进制剂改善了生物利用度的镁：体外和临床比较研究

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

While general recommendations are for 300-mg magnesium intake a day, an advanced low-dose formulation of magnesium chloride, ChronoMag (R), was designed to provide 100mg of magnesium element, thus decreasing the risk of gastrointestinal side effects and allowing long-term supplementation in health conditions related to low magnesium levels. The present study aimed to compare magnesium release profile and bioavailability between this patented low-dose continuous-release magnesium chloride tablet (100mg magnesium element) and a reference tablet at the usually prescribed dose (300mg magnesium element). Magnesium release profile was determined by dissolving the tablets in solutions simulating the gastrointestinal tract environment. A randomized double-blind crossover controlled trial of ChronoMag (R) versus reference tablet (3x100mg magnesium element tablets) in 12 normo-magnesemic healthy volunteers was conducted to evaluate the bioavailability of the patented magnesium chloride tablets (two 50mg magnesium tablets, once-a-day intake). While the reference tablet released 100% of its magnesium within 1h of dissolution, release from the magnesium chloride formulation was continuous for 6h. Cumulative urinary magnesium levels compared to those with the reference tablet were 76% (0-5h), 89% (0-10h), and 87% (0-24h). Elimination after 24h was fairly similar with both supplements. Our results suggest that the new magnesium chloride formulation, providing continuous low-dose magnesium release throughout the gastrointestinal tract, improves absorption and bioavailability. This formulation conforms to the physiological mechanism of magnesium absorption throughout the digestive tract, allowing high absorption, and may improve gastrointestinal tolerance in long-term use.
机译：虽然一般建议适用于每天300mg镁镁，但设计了一种先进的氯化镁（R）的低剂量配方，以提供100mg镁元素，从而降低胃肠道副作用的风险并长期允许长期补充与低镁水平相关的健康状况。本研究旨在比较该专利的低剂量连续释放镁氯化镁片剂（100mg镁元素）和通常规定剂量（300mg镁元素）之间的参考片之间的镁释放曲线和生物利用度。通过溶解模拟胃肠道环境的溶液中的片剂来测定镁释放曲线。进行了12位常见型志愿者的Chronomag与参考片（3x100mg镁元素片）的随机双盲交叉控制试验，以评估专利的氯化镁片剂的生物利用度（两种50mg镁片剂，一次a - 日间摄入量。虽然参考片剂在溶解的1小时内释放出100％的镁，但从氯化镁制剂中释放为连续6小时。与参考片剂相比的累积尿镁水平为76％（0-5小时），89％（0-10h）和87％（0-24h）。 24h后的消除与两种补充剂相当类似。我们的研究结果表明，新的氯化镁配方，在整个胃肠道中提供连续的低剂量镁释放，提高了吸收和生物利用度。该配方符合在整个消化道中镁吸收的生理机制，允许高吸收，并且可以在长期使用中改善胃肠道耐受性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号